Atacicept

Summary

Atacicept (CHEMBL1742986) is a phase-3 clinical-stage protein; indicated across 6 conditions including iga glomerulonephritis and lupus nephritis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 6 conditions
• Clinical trials: 18

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1742986
Name	Atacicept
Type	Protein
Max phase	3

Also known as: Atacicept, TACI-FC5, TACI-IG, ATACICEPT

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
IgA glomerulonephritis	3	MONDO:0005342	EFO:0004194
lupus nephritis	3	MONDO:0005556	EFO:0005761
rheumatoid arthritis	2	MONDO:0008383	EFO:0000685
optic neuritis	2	MONDO:0005885	EFO:0007405
multiple sclerosis	2	MONDO:0005301	MONDO:0005301
systemic lupus erythematosus	2	MONDO:0007915	MONDO:0007915

Clinical trials

Total trials: 18.

Phase distribution

Phase	Trials
PHASE2	13
PHASE2/PHASE3	2
PHASE3	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04716231	PHASE3	ACTIVE_NOT_RECRUITING	Atacicept in Subjects With IgA Nephropathy
NCT00573157	PHASE2/PHASE3	TERMINATED	The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis
NCT00624338	PHASE2/PHASE3	COMPLETED	Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
NCT05609812	PHASE3	WITHDRAWN	Atacicept in Subjects With Active Lupus Nephritis (COMPASS)
NCT06674577	PHASE2	ENROLLING_BY_INVITATION	A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
NCT06983028	PHASE2	RECRUITING	Atacicept in Multiple Glomerular Diseases
NCT07020923	PHASE2	ACTIVE_NOT_RECRUITING	Monthly Dosing of Atacicept in IgAN
NCT00430495	PHASE2	COMPLETED	A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)
NCT00595413	PHASE2	COMPLETED	Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)
NCT00624468	PHASE2	TERMINATED	Atacicept in Subjects With Optic Neuritis
NCT00642902	PHASE2	TERMINATED	A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)
NCT00664521	PHASE2	COMPLETED	Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III)
NCT00853762	PHASE2	TERMINATED	Atacicept in Multiple Sclerosis Extension Study, Phase II
NCT01440231	PHASE2	WITHDRAWN	Atacicept Demonstrating Dose RESponSe
NCT01972568	PHASE2	COMPLETED	Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
NCT02070978	PHASE2	TERMINATED	Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)
NCT02808429	PHASE2	TERMINATED	Efficacy and Safety of Atacicept in IgA Nephropathy
NCT01369628	PHASE1	TERMINATED	Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).